Measles Cases Surpassing One Thousand in U.S. 2026: Market Certainty

Polymarket has essentially closed the book on this one. The contract tracking whether U.S. measles cases will surpass 1,000 in 2026 sits at 100% probability, with $7.5 million in total volume behind that conviction. The market is not pricing uncertainty here. The market is pricing science.

The question is no longer if the U.S. crosses 1,000 cases. The related Polymarket contract for measles cases by April 30 already prices that at 95%. We are eight months from resolution on the full-year contract, and the trajectory is already beyond debate.

How the CDC Threshold Contract Works

This contract resolves YES if confirmed U.S. measles cases in 2026 exceed 1,000 by December 31, 2026. The CDC tracks and publishes case counts through its Measles Cases and Outbreaks surveillance page. Resolution depends on that official count.

• YES: U.S. measles cases exceed 1,000 in 2026. Price: $1.00. Probability: 100%. Resolves: December 31, 2026.
• NO: U.S. measles cases stay at or below 1,000 in 2026. Price: $0.00. Probability: 0%. Resolves: December 31, 2026.

A NO buyer at this point would need a near-total collapse in reported case counts, a CDC data revision, or a resolution dispute. None of those have meaningful probability. The surveillance infrastructure is established, the outbreaks are documented, and the year is less than one-third complete.

Sponsored Partner

Momentum and Market Signals

Momentum here is a non-story in the traditional sense. The 1-hour change, 24-hour change, and trend score all read flat because the contract has nowhere to move. A price of $1.00 is the ceiling. The last meaningful price action on this contract happened weeks ago, when the probability locked in at certainty. Nothing moved in the last 24 hours because no new data release could realistically reprice a contract this settled.

The liquidity picture is worth examining. Total volume stands at $7,496,401, which signals genuine, sustained conviction over the life of this market. The 24-hour volume of $1,916 is minimal, and $44,099 in available liquidity reflects a market that has done its work. New capital has little incentive to enter a fully resolved directional bet. That thin daily volume is not a warning sign here. It is the natural endpoint of a contract that the market finished pricing months ago.

Key Factors:

• Total market volume: $7,496,401 committed to YES across the contract lifetime, reflecting sustained institutional-level conviction, not a single large bet.
• 24-hour price change: +0.0%, with 7-day change also +0.0%. Price has been pinned at $1.00 with no meaningful movement.
• Related contract signal: The April 30 measles cases contract prices at 95% on Polymarket as of April 2, 2026, confirming the 1,000-case threshold is already within reach before summer.
• CDC Level 3 warning contract: Sitting at 45% on Polymarket, indicating traders see a serious but not certain escalation beyond current outbreak status.
• CDC Level 4 warning contract: At 13%, the market does not expect the most severe CDC travel advisory level, but the gap between Level 3 and Level 4 pricing is the real uncertainty story in measles markets right now.

CDC Surveillance Data and the Lines Analysis

Here is what the measurements are telling us. The U.S. recorded 285 measles cases in all of 2019, its worst year in nearly three decades at that point. The 2025 outbreak cycle pushed well past historical norms, and 2026 case counts are tracking to exceed 1,000 before most of the high-transmission season has passed. The data does not care about the politics of vaccine hesitancy debate or state-level exemption policy. The CDC surveillance numbers are what they are.

The case for YES is essentially the case for reading a thermometer. CDC confirmed case data, combined with the April 30 contract at 95%, means the 1,000 threshold is a near-mathematical certainty. Measles is one of the most transmissible pathogens tracked by the CDC, with a reproduction number above 12 in unvaccinated populations. Once an outbreak reaches critical mass in under-vaccinated communities, the case count does not reverse quickly.

The case for NO requires a scenario where CDC either stops updating its public surveillance dashboard, revises confirmed cases downward dramatically, or the contract resolves on a technicality. None of those paths carry real probability. The structural barrier to NO is the biology of measles transmission itself. Short of a mass vaccination campaign completing before year-end, which no current federal or state program is positioned to execute at that scale, the count continues upward.

Signals to Monitor:

• CDC weekly surveillance updates: Any acceleration in confirmed case counts before summer pushes the higher-threshold contracts (2k, 3k, 5k) higher and confirms the 1k contract’s resolution.
• CDC Level 3 warning contract at 45%: Movement here signals whether federal health authorities are escalating their public response, which would also confirm outbreak severity.
• State-level school exemption policy changes: Any emergency legislative action in high-outbreak states could slow transmission, but would not reverse a 2026 count already near threshold.
• MMWR outbreak reports: The CDC Morbidity and Mortality Weekly Report publishes cluster data. A multi-state outbreak report would push higher-tier contracts upward.
• International travel advisories: WHO measles outbreak declarations in source countries affect U.S. importation rates, which seed domestic spread.

The $7.5 million in total volume is the conviction signal. This is not a contract where traders are split. The market priced this outcome definitively, and the science backed it up. The market is pricing uncertainty on the scale of the outbreak now, not its existence. The higher-threshold contracts (2k, 3k, 5k) are where the live uncertainty lives in 2026 measles markets.

LINES VERDICT

LOCKED YES

U.S. measles cases crossing 1,000 in 2026 is not a prediction at this point. CDC surveillance data and the April 30 contract trajectory confirm the threshold is already within reach, with eight months remaining in the resolution window.

What the market says: One hundred percent probability backed by $7.5 million in volume. This contract has resolved in everything but name. Volatility before December 31 is effectively zero.

Key unknown: The single most consequential data release now is CDC’s weekly case count updates, which will determine whether the higher-tier contracts (2,000 and above) reprice upward. A sustained multi-state cluster reported in the MMWR would push the 2k contract significantly higher.